These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 1625513)

  • 41. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
    Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
    Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cancer and dysplasia in ulcerative colitis: a histologic study of 301 surgical specimen.
    von Herbay A; Herfarth C; Otto HF
    Z Gastroenterol; 1994 Jul; 32(7):382-8. PubMed ID: 7975773
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Pathologic diagnosis and clinical significance of gastrointestinal epithelial dysplasia in biopsy specimens].
    Yu JY
    Zhonghua Bing Li Xue Za Zhi; 2009 Feb; 38(2):77-80. PubMed ID: 19573349
    [No Abstract]   [Full Text] [Related]  

  • 44. [Colorectal lesions predisposing to cancer].
    Abdelli N; Devulder F; Bouche O; Diebold MD; Zeitoun P
    Rev Prat; 1994 Dec; 44(20):2688-93. PubMed ID: 7878357
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Morphologic findings in differential diagnosis of chronic inflammatory bowel diseases (ulcerative colitis, Crohn disease, indeterminate colitis)].
    Otto HF
    Internist (Berl); 1991 Sep; 32(9):511-7. PubMed ID: 1960018
    [No Abstract]   [Full Text] [Related]  

  • 46. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study.
    Velayos FS; Loftus EV; Jess T; Harmsen WS; Bida J; Zinsmeister AR; Tremaine WJ; Sandborn WJ
    Gastroenterology; 2006 Jun; 130(7):1941-9. PubMed ID: 16762617
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunohistochemical localization of vascular endothelial growth factor in colonic mucosa of patients with inflammatory bowel disease.
    Griga T; May B; Pfisterer O; Müller KM; Brasch F
    Hepatogastroenterology; 2002; 49(43):116-23. PubMed ID: 11941933
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reduction of colorectal cancer risk in patients with Crohn's disease.
    Lichtenstein GR
    Rev Gastroenterol Disord; 2002; 2 Suppl 2():S16-24. PubMed ID: 12478240
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Carcinoma in chronic inflammatory bowel diseases].
    von Herbay A
    Internist (Berl); 1998 Oct; 39(10):1024-9. PubMed ID: 9827371
    [No Abstract]   [Full Text] [Related]  

  • 50. Dysplasia in inflammatory bowel disease.
    Riddell RH
    Clin Gastroenterol; 1980 May; 9(2):439-58. PubMed ID: 7389177
    [No Abstract]   [Full Text] [Related]  

  • 51. Dysplasia in inflammatory bowel disease.
    Driessen A; Macken E; Moreels T; Jouret-Mourin A
    Acta Gastroenterol Belg; 2017; 80(2):299-308. PubMed ID: 29560697
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Review article: colorectal carcinoma and inflammatory bowel disease.
    Eaden J
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():24-30. PubMed ID: 15352890
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Crohn's colitis: the incidence of dysplasia and adenocarcinoma in surgical patients.
    Maykel JA; Hagerman G; Mellgren AF; Li SY; Alavi K; Baxter NN; Madoff RD
    Dis Colon Rectum; 2006 Jul; 49(7):950-7. PubMed ID: 16729218
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Implementation of image-enhanced endoscopy into solo and group practices for dysplasia detection in Crohn's disease and ulcerative colitis.
    Leong RW; Butcher RO; Picco MF
    Gastrointest Endosc Clin N Am; 2014 Jul; 24(3):419-25. PubMed ID: 24975532
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dysplasia and malignancy in inflammatory bowel disease.
    Dobbins WO
    Annu Rev Med; 1984; 35():33-48. PubMed ID: 6372661
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Review article: the effect of aminosalicylates and immunomodulation on cancer risk in inflammatory bowel disease.
    Stange EF
    Aliment Pharmacol Ther; 2006 Oct; 24 Suppl 3():64-7. PubMed ID: 16961748
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inflammatory bowel disease-related lesions in the duodenal and gastric mucosa.
    Danelius M; Ost A; Lapidus AB
    Scand J Gastroenterol; 2009; 44(4):441-5. PubMed ID: 19110988
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Surveillance of patients with chronic inflammatory intestinal diseases: problems relevant to clinical practice].
    Hoffmann R
    Praxis (Bern 1994); 1994 Oct; 83(42):1186-9. PubMed ID: 7973267
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The association of MYO9B gene in Italian patients with inflammatory bowel diseases.
    Latiano A; Palmieri O; Valvano MR; D'Incà R; Caprilli R; Cucchiara S; Sturniolo GC; Bossa F; Andriulli A; Annese V
    Aliment Pharmacol Ther; 2008 Feb; 27(3):241-8. PubMed ID: 17944996
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Cancer and Crohn's disease].
    Winkler R; Wittmer A; Heusermann U
    Z Gastroenterol; 2002 Aug; 40(8):569-76. PubMed ID: 12297980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.